Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.
Identifieur interne : 001F22 ( PubMed/Curation ); précédent : 001F21; suivant : 001F23Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.
Auteurs : Laura Marsh [États-Unis] ; Kevin Biglan ; Melissa Gerstenhaber ; James R. WilliamsSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Adrenergic Uptake Inhibitors (administration & dosage), Adrenergic Uptake Inhibitors (adverse effects), Adrenergic Uptake Inhibitors (therapeutic use), Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Bipolar Disorder (chemically induced), Cognition Disorders (drug therapy), Cognition Disorders (etiology), Drug Therapy, Combination, Female, Gastrointestinal Diseases (chemically induced), Humans, Male, Middle Aged, Nootropic Agents (administration & dosage), Nootropic Agents (adverse effects), Nootropic Agents (therapeutic use), Parkinson Disease (complications), Parkinson Disease (psychology), Pilot Projects, Prefrontal Cortex (drug effects), Prefrontal Cortex (physiopathology), Propylamines (administration & dosage), Propylamines (adverse effects), Propylamines (therapeutic use), Psychological Tests, Psychotropic Drugs (administration & dosage), Psychotropic Drugs (therapeutic use), Severity of Illness Index, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Adrenergic Uptake Inhibitors, Antiparkinson Agents, Nootropic Agents, Propylamines, Psychotropic Drugs.
- chemical , adverse effects : Adrenergic Uptake Inhibitors, Nootropic Agents, Propylamines.
- chemical , therapeutic use : Adrenergic Uptake Inhibitors, Antiparkinson Agents, Nootropic Agents, Propylamines, Psychotropic Drugs.
- chemically induced : Bipolar Disorder, Gastrointestinal Diseases.
- complications : Parkinson Disease.
- drug effects : Prefrontal Cortex.
- drug therapy : Cognition Disorders.
- etiology : Cognition Disorders.
- physiopathology : Prefrontal Cortex.
- psychology : Parkinson Disease.
- Adult, Aged, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Pilot Projects, Psychological Tests, Severity of Illness Index, Treatment Outcome.
Abstract
Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD-related ED. Twelve patients with PD and disabling ED completed an 8-week pilot open-label, flexible dose (25-100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression-Change Scale (75% positive response rate; 95% CI: 43-95%, P < 05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.
DOI: 10.1002/mds.22307
PubMed: 19025777
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001F22
Links to Exploration step
pubmed:19025777Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.</title><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. lmarsh@jhmi.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287</wicri:regionArea></affiliation></author><author><name sortKey="Biglan, Kevin" sort="Biglan, Kevin" uniqKey="Biglan K" first="Kevin" last="Biglan">Kevin Biglan</name></author><author><name sortKey="Gerstenhaber, Melissa" sort="Gerstenhaber, Melissa" uniqKey="Gerstenhaber M" first="Melissa" last="Gerstenhaber">Melissa Gerstenhaber</name></author><author><name sortKey="Williams, James R" sort="Williams, James R" uniqKey="Williams J" first="James R" last="Williams">James R. Williams</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22307</idno><idno type="RBID">pubmed:19025777</idno><idno type="pmid">19025777</idno><idno type="wicri:Area/PubMed/Corpus">001F22</idno><idno type="wicri:Area/PubMed/Curation">001F22</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.</title><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. lmarsh@jhmi.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287</wicri:regionArea></affiliation></author><author><name sortKey="Biglan, Kevin" sort="Biglan, Kevin" uniqKey="Biglan K" first="Kevin" last="Biglan">Kevin Biglan</name></author><author><name sortKey="Gerstenhaber, Melissa" sort="Gerstenhaber, Melissa" uniqKey="Gerstenhaber M" first="Melissa" last="Gerstenhaber">Melissa Gerstenhaber</name></author><author><name sortKey="Williams, James R" sort="Williams, James R" uniqKey="Williams J" first="James R" last="Williams">James R. Williams</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Uptake Inhibitors (administration & dosage)</term><term>Adrenergic Uptake Inhibitors (adverse effects)</term><term>Adrenergic Uptake Inhibitors (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Bipolar Disorder (chemically induced)</term><term>Cognition Disorders (drug therapy)</term><term>Cognition Disorders (etiology)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Gastrointestinal Diseases (chemically induced)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Nootropic Agents (administration & dosage)</term><term>Nootropic Agents (adverse effects)</term><term>Nootropic Agents (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (psychology)</term><term>Pilot Projects</term><term>Prefrontal Cortex (drug effects)</term><term>Prefrontal Cortex (physiopathology)</term><term>Propylamines (administration & dosage)</term><term>Propylamines (adverse effects)</term><term>Propylamines (therapeutic use)</term><term>Psychological Tests</term><term>Psychotropic Drugs (administration & dosage)</term><term>Psychotropic Drugs (therapeutic use)</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Antiparkinson Agents</term><term>Nootropic Agents</term><term>Propylamines</term><term>Psychotropic Drugs</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Nootropic Agents</term><term>Propylamines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Antiparkinson Agents</term><term>Nootropic Agents</term><term>Propylamines</term><term>Psychotropic Drugs</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Bipolar Disorder</term><term>Gastrointestinal Diseases</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Prefrontal Cortex</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cognition Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Prefrontal Cortex</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Psychological Tests</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD-related ED. Twelve patients with PD and disabling ED completed an 8-week pilot open-label, flexible dose (25-100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression-Change Scale (75% positive response rate; 95% CI: 43-95%, P < 05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19025777</PMID><DateCreated><Year>2009</Year><Month>02</Month><Day>02</Day></DateCreated><DateCompleted><Year>2009</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.</ArticleTitle><Pagination><MedlinePgn>277-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22307</ELocationID><Abstract><AbstractText>Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD-related ED. Twelve patients with PD and disabling ED completed an 8-week pilot open-label, flexible dose (25-100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression-Change Scale (75% positive response rate; 95% CI: 43-95%, P < 05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. lmarsh@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biglan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gerstenhaber</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01-RR00052</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038377-10</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-NS-58377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025005</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025005-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018759">Adrenergic Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011437">Propylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>ASW034S0B8</RegistryNumber><NameOfSubstance UI="C041930">atomoxetine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2001 Jul-Aug;24(4):208-13</RefSource><PMID Version="1">11479391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2008 Apr;33(5):1028-37</RefSource><PMID Version="1">17637611</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int Neuropsychol Soc. 2003 Jan;9(1):17-24</RefSource><PMID Version="1">12570354</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm. 2003 Apr;110(4):373-80</RefSource><PMID Version="1">12658365</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Saf. 2003;26(10):729-40</RefSource><PMID Version="1">12862507</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1967 May;17(5):427-42</RefSource><PMID Version="1">6067254</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Psychiatr Res. 1975 Nov;12(3):189-98</RefSource><PMID Version="1">1202204</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1984 Oct;41(10):1086-9</RefSource><PMID Version="1">6206831</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1985 Dec;142(12):1517-8</RefSource><PMID Version="1">4073327</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Psychiatr Scand Suppl. 1987;334:1-100</RefSource><PMID Version="1">2887090</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychopharmacol Bull. 1988;24(4):653-9</RefSource><PMID Version="1">3249767</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4</RefSource><PMID Version="1">1564476</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1993 Nov;43(11):2412-4</RefSource><PMID Version="1">8232972</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1994 Dec;44(12):2308-14</RefSource><PMID Version="1">7991117</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1996 Jul;61(1):70-4</RefSource><PMID Version="1">8676165</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol. 1997 Jan;244(1):2-8</RefSource><PMID Version="1">9007738</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S22-32</RefSource><PMID Version="1">9236949</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1998 Mar-Apr;21(2):108-17</RefSource><PMID Version="1">9579297</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1998 May;155(5):693-5</RefSource><PMID Version="1">9585725</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 1998 Apr;10(4):1429-35</RefSource><PMID Version="1">9749797</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</RefSource><PMID Version="1">14399272</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2005 Jul-Aug;28(4):176-8</RefSource><PMID Version="1">16062096</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Child Adolesc Psychopharmacol. 2005 Aug;15(4):664-70</RefSource><PMID Version="1">16190797</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Psychiatry. 2006 Feb;11(2):187-95</RefSource><PMID Version="1">16231039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2006 Feb 10;311(5762):861-3</RefSource><PMID Version="1">16469930</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Sci. 2006 Oct 25;248(1-2):115-9</RefSource><PMID Version="1">16765378</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2007 May;78(5):470-5</RefSource><PMID Version="1">17098845</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2007 Jul;130(Pt 7):1787-98</RefSource><PMID Version="1">17535834</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jul 15;22(9):1272-7</RefSource><PMID Version="1">17415797</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 2007 Nov 1;62(9):977-84</RefSource><PMID Version="1">17644072</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 2003 Jan 15;53(2):112-20</RefSource><PMID Version="1">12547466</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018759">Adrenergic Uptake Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005767">Gastrointestinal Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018697">Nootropic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017397">Prefrontal Cortex</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011437">Propylamines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011581">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011619">Psychotropic Drugs</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS106386</OtherID><OtherID Source="NLM">PMC2683743</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22307</ArticleId><ArticleId IdType="pubmed">19025777</ArticleId><ArticleId IdType="pmc">PMC2683743</ArticleId><ArticleId IdType="mid">NIHMS106386</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001F22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:19025777
|texte= Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19025777" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |